Bio-Techne Corporation TECH

NASDAQHealth TechnologyUnited States

$72.80+0.04 (+0.05%)

Market closed· Nov 13, 2026, 9:00 PM UTC· USD · Data may be delayed

Day's range: 72.7372.84
52-week range: 43.2072.88

Financial health

– / 5

Analyst view · 11 firms

Hold0 buy · 10 hold · 1 sell

Avg. target $73.29 (+0.7%)

Prices may be delayed and are for informational purposes only - not investment advice.

Bio-Techne Corporation TECH

NASDAQHealth TechnologyUnited States

$72.80+0.04 (+0.05%)

Market closed· Nov 13, 2026, 9:00 PM UTC· USD · Data may be delayed

Day's range: 72.7372.84
52-week range: 43.2072.88

Financial health

– / 5

Analyst view · 11 firms

Hold0 buy · 10 hold · 1 sell

Avg. target $73.29 (+0.7%)

Valuation from filings

Calculated from the tables below and the current price ($72.80) · LTM · 2026/9 · 2026-09-30

P/E: 66.79EPS $1.09
P/B: 5.29BV/share $13.76
P/S: 9.33Sales/share $7.80
Return on equity: 7.9%Net income / equity
Net margin: 14.0%Operating margin 19.6%
Free cash flow yield: 2.7%Free cash flow / market cap

Revenue and net income

Fiscal year · $ billions · net margin below

RevenueNet Income

Financial statements

$ millions · Under each value: change against a year earlier

Upgrade to MakklerPRO to see every row.Upgrade to MakklerPRO

Fiscal year	2022	2023	2024	2025	2026	LTM
Income Statement
Revenue	1,106	1,137+3%	1,159+2%	1,220+5%	1,2150%	1,228
Cost of Revenue
Gross Profit
Operating expenses
Operating Income
EBITDA
Pre-tax income
Income tax (expense) / benefit
Net Income	272	285+5%	168-41%	73-56%	182+148%	172
Earnings per share ($)
Margins
Gross margin
Operating margin
EBITDA margin
Net margin

Taken from the company's own 10-K and 10-Q filings via the SEC's XBRL data service. The "LTM" column is the last completed fiscal year plus the current year to date, minus the same period a year earlier. Lines a company tags with a non-standard label are left blank rather than filled with an approximation. Not investment advice.